The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Nonsurgical Treatment of Recurrent Glioblastoma
Open accessAbstract
Standard treatment for glioblastoma multiforme is surgery followed by radiotherapy and chemotherapy, generally with temozolomide. However, disease recurs in almost all patients. Diagnosis of progression is complex given the possibility of pseudoprogression. The Response Assessment in Neuro-Oncology criteria increase the sensitivity for detecting progression. Most patients will not be candidates for new surgery or re-irradiation, and anticancer drugs are the most common approach for second-line treatment, if the patient’s condition allows. Antiangiogenics, inhibitors of the epidermal growth factor receptor, nitrosoureas, and re-treatment with temozolomide have been studied in the second line, but a standard therapy has not yet been established. This review considers currently available medical treatment options for patients with glioblastoma recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 771
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70328-4 · Cited by 452
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372
Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
Park, J. K., Hodges, T., Arko, L., Shen, M., Dello Iacono, D., McNabb, A., Olsen Bailey, N., Kreisl, T. N., Iwamoto, F. M., Sul, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0582 · Cited by 359
Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0284 · Cited by 343
Survival and Functional Status after Resection of Recurrent Glioblastoma Multiforme
Barker, F. G., Chang, S. M., Gutin, P. H., Malec, M. K., McDermott, M. W., Prados, M. D., & Wilson, C. B. (1998) · Neurosurgery · doi:10.1097/00006123-199804000-00013 · Cited by 330
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 299
Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 264
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 231
Brandes, A. A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V, Franceschi, E., Biscuola, M., Blatt, V, Crinò, L., & Ermani, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603376 · Cited by 228
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1636 · Cited by 228
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02772 · Cited by 181
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
Doherty, L., Gigas, D. C., Kesari, S., Drappatz, J., Kim, R., Zimmerman, J., Ostrowsky, L., & Wen, P. Y. (2006) · Neurology · doi:10.1212/01.wnl.0000223844.77636.29 · Cited by 168
Raizer, J. J., Grimm, S. A., Chamberlain, M. C., Nicholas, M. K., Chandler, J. P., Muro, K., Dubner, S., RADEMAKER, A. W., Renfrow, J. J., & Bredel, M. (2010) · Cancer · doi:10.1002/cncr.25462 · Cited by 153
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
Yung, W. K. A., Vredenburgh, J. J., Cloughesy, T. F., Nghiemphu, P. L., Klencke, B. J., GILBERT, M. R., Reardon, D. A., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq072 · Cited by 148
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
Brandes, A. A., Tosoni, A., Amistà, P., Nicolardi, L., Grosso, D., Berti, F., & Ermani, M. (2004) · Neurology · doi:10.1212/01.wnl.0000140495.33615.ca · Cited by 134
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9957-6 · Cited by 124
de Groot, J., Gilbert, M. R., Aldape, K., Hess, K. R., Hanna, T., Ictech, S. E., Groves, M. D., Conrad, C., Colman, H., Puduvalli, V. K., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9637-y · Cited by 121
Little, M. P., Rajaraman, P., Curtis, R. E., Devesa, S. S., Inskip, P. D., Check, D. P., & Linet, M. S. (2012) · BMJ · doi:10.1136/bmj.e1147 · Cited by 110
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Reithmeier, T., Graf, E., Piroth, T., Trippel, M., Pinsker, M. O., & Nikkhah, G. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-30 · Cited by 107
Gilbert, M. R., Dignam, J. J., Won, M., Blumenthal, D. T., Vogelbaum, M. A., Aldape, K., Colman, H., Chakravarti, A., Jeraj, R., Armstrong, T. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.1 · Cited by 105
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Norden, A. D., Lesser, G. J., Drappatz, J., Ligon, K. L., Hammond, S. N., Lee, E. Q., Reardon, D., Fadul, C. E., Plotkin, S. R., Batchelor, T. T., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not040 · Cited by 92
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
Brandes, A. A., Ermani, M., Basso, U., Amistà, P., Berti, F., Scienza, R., Rotilio, A., Pinna, G. D., Gardiman, M. P., & Monfardini, S. (2001) · Annals of Oncology · doi:10.1023/a:1008336732273 · Cited by 91
PCV chemotherapy for recurrent glioblastoma
Schmidt, F., Fischer, J., Herrlinger, U., Dietz, K., DICHGANS, J., & Weller, M. (2006) · Neurology · doi:10.1212/01.wnl.0000197792.73656.c2 · Cited by 89
Reardon, D. A., Desjardins, A., Peters, K. B., Vredenburgh, J. J., Gururangan, S., Sampson, J. H., McLendon, R. E., Herndon, J. E., Sykes, A. D., Threatt, S., et al. (2011) · Cancer · doi:10.1002/cncr.26188 · Cited by 88
Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
Bregy, A., Wong, T. M., Shah, A. H., Goldberg, J. M., & Komotar, R. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.007 · Cited by 78
Uhm, J. H. (2010) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(10)79301-7 · Cited by 78
Zhang, G., Huang, S., & Wang, Z. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.12.028 · Cited by 72
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
Addeo, R., Caraglia, M., Santi, M. S. D., Montella, L., Abbruzzese, A., Parlato, C., Vincenzi, B., Carraturo, M., Faiola, V., Genovese, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0329-z · Cited by 70
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich, F., Landi, L. M., Lombardi, G., Porta, C., Galli, L., Fontana, A., AMOROSO, D., Galli, C., Andreuccetti, M., Falcone, A., et al. (2013) · PubMed · Cited by 69
Wen, P. Y., Prados, M. D., Schiff, D., Reardon, D. A., Cloughesy, T. F., Mikkelsen, T., Batchelor, T. T., Drappatz, J., Chamberlain, M. C., & de Groot, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2006 · Cited by 67
Francesconi, A. B., Dupre, S., Matos, M., Martin, D., Hughes, B. G. M., Wyld, D., & Lickliter, J. D. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.12.009 · Cited by 62
Balmaceda, C. M., Peereboom, D. M., Pannullo, S. C., Cheung, Y. K., Fisher, P. G., Alavi, J. Β., Sisti, M. B., Chen, J., & Fine, R. L. (2008) · Cancer · doi:10.1002/cncr.23167 · Cited by 61
Brandes, A. A., Ermani, M., Basso, U., Paris, M. K., Lumachi, F., Berti, F., Amistà, P., Gardiman, M. P., Iuzzolino, P., Turazzi, S., et al. (2002) · Oncology · doi:10.1159/000065718 · Cited by 59
Stupp, R., Wong, E., Scott, C., Taillibert, S., Kanner, A. A., Kesari, S., Ram, Z., & on behalf of the, E. F. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou265.40 · Cited by 57
Extended-schedule dose-dense temozolomide in refractory gliomas
GENOM Cooperative Group, Berrocal, A., Segura, P. P., Gil, M., Balañá, C., López, J. G., Yayá, R., Rodríguez, J., Reynés, G., Gallego, O. S., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9980-7 · Cited by 56
Self-citationContinuous low-dose temozolomide and celecoxib in recurrent glioblastoma
Stockhammer, F., Misch, M., Koch, A., Czabanka, M., Plotkin, M., Blechschmidt, C., Tuettenberg, J., & Vajkoczy, P. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0192-y · Cited by 56
Immunological challenges for peptide-based immunotherapy in glioblastoma
Mohme, M., Neidert, M. C., Regli, L., Weller, M., & Martinꝉ, R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.08.008 · Cited by 53
Gallego, O. S., Cuatrecasas, M., Benavides, M., Segura, P. P., Berrocal, A., Erill, N., Colomer, A., Quintana, M. J., Balañá, C., Gil, M., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1316-y · Cited by 50
Self-citationACNU-based chemotherapy for recurrent glioma in the temozolomide era
Hertler, C., Roth, P., Wick, W., Steinbach, J. P., Linnebank, M., Weller, M., & Eisele, G. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9728-9 · Cited by 46
Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study.
Zustovich, F., Landi, L. M., Lombardi, G., Galli, L., Porta, C., AMOROSO, D., Fontana, A., Andreuccetti, M., Galli, C., Falcone, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2080 · Cited by 26
Cited by
Chen, R. J., Lu, M. Y., Wang, J., Williamson, D. F. K., Rodig, S. J., Lindeman, N. I., & Mahmood, F. (2022) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2020.3021387 · Cited by 729
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00963 · Cited by 322
Kim, G., Kim, M., Lee, Y., Byun, J. W., Hwang, D. W., & Lee, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.009 · Cited by 311
Egeland, M., Guinaudie, C., Du Preez, A., Musaelyan, K., Zunszain, P. A., Fernandes, C., Pariante, C. M., & Thuret, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.68 · Cited by 98
Metadata
- Authors
- Gallego, O.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2015-08-01
- Volume
- 22
- Issue
- 4
- Pages
- 273-281
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- OpenAlex
- W1881534971
- Cited by
- 296
- References
- 64
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.